セマグルチドの世界市場：市場規模・シェア・動向分析 (製品別・用途別・投与経路別・流通チャネル別・地域別)、セグメント別予測 (2025年～2035年)

セマグルチド市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のセマグルチドの市場規模は2035年までに936億米ドルに達し、予測期間中にCAGR 10.47％で成長すると予測されています。

セマグルチド業界は、世界の糖尿病と肥満の有病率の増加に牽引されて成長を遂げています。糖尿病管理におけるグルカゴン様ペプチド-1受容体作動薬（GLP-1 RA）の需要の増加は、セマグルチドを重要な治療選択肢として位置付けています。同市場は、規制当局の承認、臨床適応の拡大、先進的な糖尿病・肥満治療薬の採用を支える医療費の増加などの影響を受けています。

セマグルチド市場の主な促進要因としては、2型糖尿病と肥満の負担増が挙げられ、効果的な治療介入に対する需要が高まっています。心血管リスクの低減と体重管理の補助という治療薬の有効性により、糖尿病治療以外の用途も拡大しています。さらに、有利な償還政策や自己投与注射療法の採用拡大も市場成長に寄与しています。ドラッグデリバリー機構の改善を目指した継続的な研究開発活動は、その商業的可能性をさらに高めています。

医療インフラ投資の増加と糖尿病管理に対する意識の高まりにより、市場は新興経済圏で拡大する可能性があります。また、セマグルチドが体重減少に有効であることが実証され、複数の地域で承認に至ったことから、肥満治療においてもさらなる市場浸透の可能性があります。製薬会社は、患者のコンプライアンスを高め、市場参入の幅を広げるため、経口剤や併用療法を含む新規製剤の開発に積極的に取り組んでいます。

セマグルチド業界は、高い研究開発投資、厳格な規制監督、強力な知的財産保護を特徴としています。大手製薬企業が業界を支配し、広範な流通網とパートナーシップを活用して市場での存在感を高めています。競合環境は、進行中の臨床試験、製品ライフサイクル管理戦略、製剤の進歩や適応拡大による製品の差別化努力によって形成されています。

セマグルチドは、製剤、製造方法、治療用途をカバーする複数の特許で保護されています。セマグルチドの主要な特許は2030年代まで延長されており、ジェネリック医薬品の競合を制限し、主要メーカーの市場独占権を継続的に確保しています。経口剤や徐放性製剤などの代替製剤に投資している企業は、当初の有効期限を越えて商業的利用可能性を拡大するため、さらなる特許保護を求めています。

最近の市場事例としては、肥満治療などの新しい治療領域でセマグルチドが承認され、その商業的可能性が大幅に拡大したことが挙げられます。また、市場リーダーは戦略的提携や買収を行い、販売能力を強化しています。さらに、既存の治療薬と比較して優れた有効性が実証された臨床試験の結果は、市場での採用を強化し、次世代製剤へのさらなる投資を促しています。

セマグルチド業界は、糖尿病と肥満の有病率の増加、ドラッグデリバリーの技術進歩、継続的な研究開発イニシアチブに支えられ、持続的な成長を遂げる態勢にあります。特許保護により当面の市場独占性は確保されているもの、代替製剤や併用療法の登場により競争力学は変化する可能性があります。業界参入企業は、進化する市場情勢に対応するため、適応症と地域情勢の拡大に引き続き注力しています。

セマグルチド市場：分析概要

• 製品種類別では、オゼンピックが2024年の売上高シェア59.62%で市場を席巻、強力な臨床効果、幅広い規制当局の承認、2型糖尿病への採用拡大が牽引。
• 用途別では、2型糖尿病が市場を席巻し、2024年の売上高シェアは71.16%でした。
• 投与経路別では、非経口投与経路が市場を席巻し、2024年には88.46%のシェアを占めました。
• 販売チャネル別では、小売薬局が市場をリードし、2024年には55.09%のシェアを占めています。
• 主な市場参入企業は、ノボ・ノルディスク、イーライリリー、バイキング・セラピューティクス、レキシコン・ファーマシューティカルズ、バイオコン、アストラゼネカなどです。セマグルチドの特許が切れた後、バイオシミラーメーカーが市場に参入するため、競合は激化すると予想されます。
• 2025年3月、ノボノルディスクの第3b相STRIDE試験は、オゼンピック（セマグルチド1.0mg）が2型糖尿病とPADを有する成人患者において歩行距離を13％改善することを示しました。結果はACC2025で発表され、Lancet誌に掲載されました。ノボノルディスク社は、EMAとFDAにラベル延長申請を提出しました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 セマグルチド市場：変動要因・傾向・範囲

• 市場連関の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析：相別
  • 特許満了分析
  • 価格分析
  • 競合情勢：特許取得後のセマグルチド市場における新興バイオシミラー

第4章 セマグルチド市場：製品別のビジネス分析

• 市場シェア：製品別 (2024年・2035年)
• 製品別ダッシュボード
• 市場規模の予測と動向分析：製品別 (2018～2035年)
• オゼンピック
• ウェゴヴィ
• リュベルスス
• その他

第5章 セマグルチド市場：用途別のビジネス分析

• 市場シェア：用途別 (2024年・2035年)
• 用途別ダッシュボード
• 市場規模の予測と動向分析：用途別 (2018～2035年)
• 2型糖尿病
• 肥満
• その他

第6章 セマグルチド市場：投与経路別のビジネス分析

• 市場シェア：投与経路別 (2024年・2035年)
• 投与経路別ダッシュボード
• 市場規模の予測と動向分析：投与経路別 (2018～2035年)
• 非経口
• 経口

第7章 セマグルチド市場：流通チャネル別のビジネス分析

• 市場シェア：流通チャネル別 (2024年・2035年)
• 流通チャネル別ダッシュボード
• 市場規模の予測と動向分析：流通チャネル別 (2018～2035年)
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 セマグルチド市場：地域別のビジネス分析

• 市場シェア：地域別 (2024年・2035年)
• 地域別ダッシュボード
• 市場規模の予測と動向分析：地域別 (2018～2035年)
• 北米
  • 国別（2018～2035年）
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業概要
• 企業の市場ポジション分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novo Nordisk A/S
  • Eli Lilly
  • Viking Therapeutics
  • Lexicon Pharmaceuticals
  • Biocon
  • AstraZeneca

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global semaglutide market, by region, 2018 - 2035 (USD Million)
• Table 4. Global semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 5. Global semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 6. Global semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 7. Global semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 8. North America semaglutide market, by country, 2018 - 2035 (USD Million)
• Table 9. North America semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 10. North America semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 11. North America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 12. North America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 13. U.S. semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 14. U.S. Semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 15. U.S. semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 16. U.S. semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 17. Canada semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 18. Canada semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 19. Canada semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 20. Canada semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 21. Mexico semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 22. Mexico semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 23. Mexico semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 24. Mexico semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 25. Europe semaglutide market, by country, 2018 - 2035 (USD Million)
• Table 26. Europe semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 27. Europe semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 28. Europe semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 29. Europe semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 30. UK semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 31. UK Semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 32. UK semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 33. UK semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 34. Germany semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 35. Germany semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 36. Germany semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 37. Germany semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 38. France semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 39. France Semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 40. France semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 41. France semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 42. Italy semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 43. Italy semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 44. Italy semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 45. Italy semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 46. Spain semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 47. Spain semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 48. Spain semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 49. Spain semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 50. Norway semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 51. Norway Semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 52. Norway semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 53. Norway semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 54. Denmark semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 55. Denmark semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 56. Denmark semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 57. Denmark semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 58. Sweden semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 59. Sweden semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 60. Sweden semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 61. Sweden semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 62. Asia Pacific semaglutide market, by country, 2018 - 2035 (USD Million)
• Table 63. Asia Pacific semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 64. Asia Pacific semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 65. Asia Pacific semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 66. Asia Pacific semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 67. Japan semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 68. Japan semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 69. Japan semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 70. Japan semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 71. China semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 72. China semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 73. China semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 74. China semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 75. India semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 76. India semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 77. India semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 78. India semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 79. Australia semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 80. Australia semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 81. Australia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 82. Australia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 83. South Korea semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 84. South Korea semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 85. South Korea semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 86. South Korea semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 87. Thailand semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 88. Thailand semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 89. Thailand semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 90. Thailand semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 91. Latin America semaglutide market, by country, 2018 - 2035 (USD Million)
• Table 92. Latin America semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 93. Latin America semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 94. Latin America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 95. Latin America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 96. Brazil semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 97. Brazil semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 98. Brazil semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 99. Brazil semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 100. Argentina semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 101. Argentina semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 102. Argentina semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 103. Argentina semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 104. Middle East & Africa Semaglutide market, by country, 2018 - 2035 (USD Million)
• Table 105. Middle East & Africa semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 106. Middle East & Africa semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 107. Middle East & Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 108. Middle East & Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 109. South Africa semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 110. South Africa semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 111. South Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 112. South Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 113. Saudi Arabia semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 114. Saudi Arabia semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 115. Saudi Arabia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 116. Saudi Arabia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 117. UAE semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 118. UAE semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 119. UAE semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 120. UAE semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
• Table 121. Kuwait semaglutide market, by product, 2018 - 2035 (USD Million)
• Table 122. Kuwait semaglutide market, by application, 2018 - 2035 (USD Million)
• Table 123. Kuwait semaglutide market, by route of administration, 2018 - 2035 (USD Million)
• Table 124. Kuwait semaglutide market, by distribution channel, 2018 - 2035 (USD Million)

List of Figures

• Fig. 1 Semaglutide market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Semaglutide market dynamics
• Fig. 12 Semaglutide market: Porter's five forces analysis
• Fig. 13 Semaglutide market: PESTLE analysis
• Fig. 14 Product market, 2018 - 2035 (USD Million)
• Fig. 15 Ozempic market, 2018 - 2035 (USD Million)
• Fig. 16 Wegovy market, 2018 - 2035 (USD Million)
• Fig. 17 Rybelsus market, 2018 - 2035 (USD Million)
• Fig. 18 Others market, 2018 - 2035 (USD Million)
• Fig. 19 Application market, 2018 - 2035 (USD Million)
• Fig. 20 Type 2 Diabetes Mellitus market, 2018 - 2035 (USD Million)
• Fig. 21 Obesity market, 2018 - 2035 (USD Million)
• Fig. 22 Others market, 2018 - 2035 (USD Million)
• Fig. 23 Route of Administration market, 2018 - 2035 (USD Million)
• Fig. 24 Parenteral market, 2018 - 2035 (USD Million)
• Fig. 25 Oral market, 2018 - 2035 (USD Million)
• Fig. 26 Distribution Channel market, 2018 - 2035 (USD Million)
• Fig. 27 Hospital Pharmacies market, 2018 - 2035 (USD Million)
• Fig. 28 Retail Pharmacies market, 2018 - 2035 (USD Million)
• Fig. 29 Online Pharmacies market, 2018 - 2035 (USD Million)
• Fig. 30 Semaglutide market revenue, by region
• Fig. 31 Regional marketplace: Key takeaways
• Fig. 32 Regional marketplace: Key takeaways
• Fig. 33 North America semaglutide market, 2018 - 2035 (USD Million)
• Fig. 34 U.S. country dynamics
• Fig. 35 U.S. semaglutide market, 2018 - 2035 (USD Million)
• Fig. 36 Canada country dynamics
• Fig. 37 Canada semaglutide market, 2018 - 2035 (USD Million)
• Fig. 38 Mexico country dynamics
• Fig. 39 Mexico semaglutide market, 2018 - 2035 (USD Million)
• Fig. 40 Europe semaglutide market, 2018 - 2035 (USD Million)
• Fig. 41 UK country dynamics
• Fig. 42 UK semaglutide market, 2018 - 2035 (USD Million)
• Fig. 43 Germany country dynamics
• Fig. 44 Germany semaglutide market, 2018 - 2035 (USD Million)
• Fig. 45 France country dynamics
• Fig. 46 France semaglutide market, 2018 - 2035 (USD Million)
• Fig. 47 Italy country dynamics
• Fig. 48 Italy semaglutide market, 2018 - 2035 (USD Million)
• Fig. 49 Spain country dynamics
• Fig. 50 Spain semaglutide market, 2018 - 2035 (USD Million)
• Fig. 51 Norway country dynamics
• Fig. 52 Norway semaglutide market, 2018 - 2035 (USD Million)
• Fig. 53 Sweden country dynamics
• Fig. 54 Sweden semaglutide market, 2018 - 2035 (USD Million)
• Fig. 55 Denmark country dynamics
• Fig. 56 Denmark semaglutide market, 2018 - 2035 (USD Million)
• Fig. 57 Asia Pacific semaglutide market, 2018 - 2035 (USD Million)
• Fig. 58 Japan country dynamics
• Fig. 59 Japan semaglutide market, 2018 - 2035 (USD Million)
• Fig. 60 China country dynamics
• Fig. 61 China semaglutide market, 2018 - 2035 (USD Million)
• Fig. 62 India country dynamics
• Fig. 63 India semaglutide market, 2018 - 2035 (USD Million)
• Fig. 64 Australia country dynamics
• Fig. 65 Australia semaglutide market, 2018 - 2035 (USD Million)
• Fig. 66 South Korea country dynamics
• Fig. 67 South Korea semaglutide market, 2018 - 2035 (USD Million)
• Fig. 68 Thailand country dynamics
• Fig. 69 Thailand semaglutide market, 2018 - 2035 (USD Million)
• Fig. 70 Latin America semaglutide market, 2018 - 2035 (USD Million)
• Fig. 71 Brazil country dynamics
• Fig. 72 Brazil semaglutide market, 2018 - 2035 (USD Million)
• Fig. 73 Argentina country dynamics
• Fig. 74 Argentina semaglutide market, 2018 - 2035 (USD Million)
• Fig. 75 MEA semaglutide market, 2018 - 2035 (USD Million)
• Fig. 76 South Africa country dynamics
• Fig. 77 South Africa semaglutide market, 2018 - 2035 (USD Million)
• Fig. 78 Saudi Arabia country dynamics
• Fig. 79 Saudi Arabia semaglutide market, 2018 - 2035 (USD Million)
• Fig. 80 UAE country dynamics
• Fig. 81 UAE semaglutide market, 2018 - 2035 (USD Million)
• Fig. 82 Kuwait country dynamics
• Fig. 83 Kuwait semaglutide market, 2018 - 2035 (USD Million)
• Fig. 84 Company categorization
• Fig. 85 Company market position analysis
• Fig. 86 Strategic framework

Semaglutide Market Growth & Trends:

The global semaglutide market size is anticipated to reach USD 93.60 billion by 2035, growing at a CAGR of 10.47% during the forecast period, according to a new report by Grand View Research, Inc. The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments.

The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial potential.

The market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market reach.

The semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded indications.

Semaglutide is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration dates.

Recent market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation formulations.

The semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market landscape.

Semaglutide Market Report Highlights:

• Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes.
• Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
• Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations.
• Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy.
• Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires.
• In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Semaglutide Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis, by Phase
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis
  • 3.3.6. Competitive Landscape: Emerging Biosimilars in the Post-Patent Semaglutide Market

Chapter 4. Semaglutide Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2035
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)
• 4.4. Ozempic
  • 4.4.1. Ozempic Market, 2018 - 2035 (USD Million)
• 4.5. Wegovy
  • 4.5.1. Wegovy Market, 2018 - 2035 (USD Million)
• 4.6. Rybelsus
  • 4.6.1. Rybelsus Market, 2018 - 2035 (USD Million)
• 4.7. Others
  • 4.7.1. Other Product Market, 2018 - 2035 (USD Million)

Chapter 5. Semaglutide Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2035
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)
• 5.4. Type 2 Diabetes Mellitus
  • 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2035 (USD Million)
• 5.5. Obesity
  • 5.5.1. Obesity Market, 2018 - 2035 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2035 (USD Million)

Chapter 6. Semaglutide Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2035
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral Market, 2018 - 2035 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2018 - 2035 (USD Million)

Chapter 7. Semaglutide Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2035
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2035 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2035 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2035 (USD Million)

Chapter 8. Semaglutide Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2035
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2035:
• 8.4. North America
  • 8.4.1. North America Semaglutide Market Estimates And Forecasts, By Country, 2018 - 2035 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novo Nordisk A/S
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Viking Therapeutics
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Lexicon Pharmaceuticals
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Biocon
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives